News
July 2025
July 17th 2025: CARDINOR IS ACQUIRED BY IC TARGETS AS
IC Targets AS (ICT) has acquired a 92 % stake in CardiNor AS, a Norwegian diagnostics company committed to combating the heart failure (HF) epidemic through its patented blood biomarker, secretoneurin (SN). We see strong synergies between the two companies’ diagnostic solutions for heart failure: CardiNor’s low-cost SN blood test and the proprietary MRI contrast agent mangafodipir from ICT. Elevated SN levels are a strong indicator that cardiac MRI should be performed to assess for structural or functional heart disease.
October 2022
Secretoneurin: a potential complementary cardiovascular biomarker
Secretoneurin is a novel prognostic biomarker that may predict mortality in heart failure and the occurrence of ventricular arrhythmias. Clinical Laboratory International (CLI) caught up with Professor Torbjørn Omland (University of Oslo, Oslo, Norway) to find out more about it.
September 2022
Secretoneurin: the next biomarker for cardiovascular disease.
Secretoneurin is a small neuropeptide detectable in the blood and is strong predictor for mortality in several patient cohorts with underlying cardiovascular disease. Here CardiNor introduce themselves and their work to develop a secretoneurin test to use as part of a biomarker panel for cardiovascular disease.